VANCOUVER, BC, February 3, 2022 /CNW/ – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSXV: NU) (OTC PINK: NRXCF) (FRANKFURT: 1N9), an innovative technology company developing products, licensing, intellectual property and technologies for B2B partnerships and the nutraceutical industry, is pleased to provide the following update.
Tablet : At January 17andthe Company shipped an order of 45,000 sticks to Tabletz for distribution in Japan. The product was received by Tabletzs distribution partner, CFC Japan Co., for subsequent distribution across the country to a national grocery chain, select convenience stores, and to restock Biopole stores. Although some shipping challenges remain, for the most part the company has overcome these challenges and is well positioned for future shipments to Japan. The company is working on fulfilling an additional order to restock existing stores as well as building product for new stores to go live. Tabletz implements a comprehensive marketing campaign in Japan which includes social media, traditional media, in-store programs and sampling programs where Covid restrictions permit. The next order should be shipped in the second quarter. Further details on distribution partners, marketing initiatives and stores will follow.
Cryopharma: Partner of Cryopharm, Red Bud Rootscompleted manufacturing and began distribution and sales of a small product launch order which initially includes gummies, in the marketplace. red bud is distributed in 275 locations. They have licenses for infusion, cultivation, extraction, sale and distribution. NeutriSci is expected to realize revenue from its licensing agreement with Cryopharm in the second quarter of this year. Cryopharm also continues to move forward with its partnership with a Oklahoma group. They have been working on deployment requirements and will continue to do so through Q3. The timing of the start of production is still unknown at this time.
Neuenergy: NeutriSci’s latest tablet production for neuenergy® made its way to its national distribution partner, ANB. The initial order of 1,500 cases will be placed in ANB’s distribution channel in Canada. Retailers include Overwaitea, Mckesson, Sobey’s, Safeway, Pharmasave and Guardian. Previously announced partnership and order with German marketing and distribution group, THIC, is on track to begin distributing neuenergy® on the European market in Q2. A first order for 10,000 units of resealable bulk bags of 36 tablets each has already been placed and a deposit has been received. The company and THIC plan to release packaging, distribution and sales details in the coming weeks.
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Founded in 2009, NeutriSci’s builds sustainable sales models with convenience, chain drug, mass market and supermarket retailers for its products offering co-branding opportunities as well as private label opportunities and services contract manufacturing. For more information, visit: www.neutrisci.com.
On behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
Tel: (403) 264-6320
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements contained herein, other than statements of historical fact, should be considered forward-looking. Although the Company believes that the expectations expressed in these forward-looking statements are based on reasonable assumptions, these statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include market prices, the continued availability of capital and financing, and general economic, market or business conditions. There can be no assurance that such statements will prove to be accurate and, therefore, readers are urged to rely on their own assessment of such uncertainties. We undertake no obligation to update forward-looking statements, except as required by applicable law.
The statements in this press release have not been evaluated by the Food and Drug Administration. The products or ingredients are not intended to diagnose, treat, cure or prevent any disease.
SOURCE NeutriSci International Inc.
For further information: For investor inquiries, please contact [email protected]